Insights

Brussels and Doha – April 1, 2024: The Legal 500 Europe, Middle East & Africa (EMEA) 2024 edition has recognized 16 practice areas and 11 lawyers in Crowell & Moring’s Brussels and Doha offices. The 11 individual lawyers received 18 total rankings across the 16 different practice areas.

Brussels – April 13, 2022:  The Legal 500 Europe, Middle East & Africa (EMEA) 2022 edition has recognized 11 practice areas and seven lawyers in Crowell & Moring’s Brussels office. The seven individual lawyers received 12 total rankings across all practice areas. The publication seeks to “highlight the practice area teams who are providing the most cutting edge and innovative advice to corporate counsel.”

Brussels – April 16, 2021: The Legal 500 Europe, Middle East & Africa (EMEA) 2021 edition has recognized 11 practice areas and seven lawyers in Crowell & Moring’s Brussels office. The seven individual lawyers received 11 total rankings across all practice areas. The publication seeks to “highlight the practice area teams who are providing the most cutting edge and innovative advice to corporate counsel.”

The number of medical devices with wireless and network-connected capabilities continues to grow. At the same time, by some reports the number of ransomware attacks on health care facilities has more than doubled in recent years.[1] Recent cyberattacks and/or ransomware attacks on healthcare systems have resulted in stolen patient data, emergency room closures, diversion of ambulances, and cancellation of surgeries and other appointments. Given the potential disruptions in patient care in connection with these incidents, the cybersecurity of medical devices with wireless and network-connected capabilities becomes increasingly important to avoid and mitigate these possible impacts.

Although the Patent Trial & Appeal Board’s (PTAB) reliance on Fintiv to deny petitions for Inter Partes Review (IPR) has waned since Kathi Vidal was named Director of the USPTO and the advent of Sotera stipulations, these so-called Fintiv denials remain the subject of intense scrutiny by the patent bar. On March 13, 2023, the Federal Circuit Court of Appeals revived a challenge to the PTAB’s practice of discretionary denials under Fintiv, allowing it to proceed before the district court.[1] This revival will no doubt be welcomed by patent challengers who dislike the PTAB’s current practice under Fintiv.

In Brown v. GlaxoSmithKline, LLC and Providence Health System – Oregon, 323 Or. App. 214 (Ct. App. Or. 2022), the Oregon Court of Appeals recently found that a hospital could be a “seller” of pharmaceutical drugs under Oregon law, subjecting it to strict products liability for alleged drug defects.  This decision contravenes—and thus threatens to upset—the overwhelming consensus among U.S. courts that hospitals are not strictly liable for allegedly defective drugs or medical devices used in the course of providing medical care to patients. 

More companies than ever before are launching smart medical devices and industry growth seems endless as new products and technologies are announced daily. However, before companies push products to market, it’s crucial to understand key aspects of device approval, and company and patient protection. In this webinar, our speakers will outline intellectual property strategies, U.S. Food and Drug Administration considerations, and data cybersecurity concerns that are inherent to all smart medical devices. They will explore the legal issues that can significantly decrease the risk profile and potential liabilities throughout a product's lifecycle and create safer, more reliable products for consumers.

ACI’s Drug and Medical Device Litigation conference is the only event which brings together an exceptional in-house presence on the faculty, the top defense firms representing pharmaceutical and medical device companies, experienced jurists from around the country, the FDA, and the DOJ. Designed for both networking and masters-level strategy sharing, this is the leading forum at which to learn winning life sciences products liability litigation strategies.